Role of bronchodilators in chronic obstructive pulmonary disease

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 2, 2005, Pages 221-234

  Weder, Max M ^a   Donohue, James F ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Bronchodilators; COPD; Therapy guidelines

Indexed keywords

ADENOSINE TRIPHOSPHATASE; AMINOPHYLLINE; BECLOMETASONE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CHLOROFLUOROCARBON; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FLUORINATED HYDROCARBON; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; ISOPRENALINE; LEVALBUTEROL; METHYLPREDNISOLONE; OXITROPIUM BROMIDE; PHOSPHODIESTERASE IV INHIBITOR; PIRBUTEROL; POTASSIUM; PREDNISOLONE; ROFLUMILAST; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE DERIVATIVE; TIOTROPIUM BROMIDE; TRIAMCINOLONE;

AGING; BRONCHODILATATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COLITIS; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LUNG CAPACITY; LUNG FUNCTION TEST; METERED DOSE INHALER; NAUSEA; NEBULIZER; PATHOPHYSIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SEIZURE; SIDE EFFECT; TACHYCARDIA; TREATMENT PLANNING; TREMOR; VAGUS NERVE STIMULATION; VOMITING; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; BRONCHODILATOR AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; GUIDELINES; HUMANS; MALE; MUCOCILIARY CLEARANCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 18144411638     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-869541     Document Type: Review

References (66)

1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/ WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163:1256-1276
2. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-2653
3. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012
4. 1. The Lung Health Study. JAMA 1994;272:1497-1505
5. Vestbo J. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J 2004;24:206-210
6. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-664
7. Dorinsky PM, Reisner C, Ferguson GT, Menjoge SS, Serby CW, Witek TJ Jr. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest 1999;115:966-971
8. Donohue JF, Anderson W, Wiesniewski M, et al. Demographics and bronchoreversibility of salmeterol and ipratropium in a large population of patients with mild-to-moderate COPD [abstract]. Am J Respir Crit Care Med 1997;155: A227
9. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:1084-1091
10. Anthonisen NR, Wright EC. Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986;133:814-819
11. Tashkin D, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest 2003;123:1441-1449
12. Di Marco F, Milic-Emili J, Boveri B, et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003;21:86-94
13. Newton MF, O'Donnell DE, Forkert L. Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 2002;121:1042-1050
14. Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am J Respir Crit Care Med 1994;150(5 Pt 1):1256-1261
15. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir Care 2002;47:1406-1416 discussion 1416-1418
16. Green SA, Spasoff AP, Coleman RA, Johnson M, Liggett SB. Sustained activation of a G protein-coupled receptor via "anchored" agonist binding: molecular localization of the salmeterol exosite within the 2-adrenergic receptor. J Biol Chem 1996;271:24029-24035
17. Barnes PJ. Beta-adrenergic receptors and their regulation. Am J Respir Crit Care Med 1995;152:838-860
18. Ram FS, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003;58:580-584
19. Sin DD, McAlister FA, Man SF, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301-2312
20. Sears MR. Adverse effects of beta-agonists. J Allergy Clin Immunol 2002;110(suppl 6):S322-S328
21. Schultze-Werninghaus G. Multicenter 1-year trial on formoterol, a new long-acting beta 2-agonist, in chronic obstructive airway disease. Lung 1990;168(suppl):83-89
22. Appleton S, Poole P, Smith B, Veale A, Bara A. Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev 2002;3CD002986
23. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-1289
24. Taccola M, Bancalari L, Ghignoni G, Paggiaro PL. Salmeterol versus slow-release theophylline in patients with reversible obstructive pulmonary disease. Monaldi Arch Chest Dis 1999;54:302-306
25. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999;66:434-439
26. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest 2003;123:1817-1824
27. Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003;97:1014-1020
28. Nelson HS, Bensch G, Pleskow WW, et al. Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma. J Allergy Clin Immunol 1998;102(6 Pt 1):943-952
29. Gawchik SM, Saccar CL, Noonan M, Reasner DS, DeGraw SS. The safety and efficacy of nebulized levalbuterol compared with racemic albuterol and placebo in the treatment of asthma in pediatric patients. J Allergy Clin Immunol 1999;103:615-621
30. Nowak RM, Emerman CL, Schaefer K, Disantostefano RL, Vaickus L, Roach JM. Levalbuterol compared with racemic albuterol in the treatment of acute asthma: results of a pilot study. Am J Emerg Med 2004;22:29-36
31. Carl JC, Myers TR, Kirchner HL, Kercsmar CM. Comparison of racemic albuterol and levalbuterol for treatment of acute asthma. J Pediatr 2003;143:731-736
32. Truitt T, Witko J, Halpern M. Levalbuterol compared to racemic albuterol: efficacy and outcomes in patients hospitalized with COPD or asthma. Chest 2003;123:128-135
33. Salathe M. Effects of beta-agonists on airway epithelial cells. J Allergy Clin Immunol 2002;110(suppl 6):S275-S281
34. Farmer P, Pugin J. Beta-adrenergic agonists exert their "anti-inflammatory" effects in monocytic cells through the IkappaB/NF-kappaB pathway. Am J Physiol Lung Cell Mol Physiol 2000;279:L675-L682
35. Factor P, Adir Y, Mutlu GM, Burhop J, Dumasius V. Effects of beta2-adrenergic receptor overexpression on alveolar epithelial active transport. J Allergy Clin Immunol 2002;110(suppl 6):S242-S246
36. Philipson LH. Beta-agonists and metabolism. J Allergy Clin Immunol 2002;110(6 Suppl):S313-S317
37. Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 2002;110(suppl 6):S261-S268
38. Hanania NA, Darken P, Horstman D, et al. The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 2003;124:834-843
39. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456
40. Nannini L, Cates CJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta-agonist in one inhaler for chronic obstructive pulmonary disease. Cochrane Database Syst Rev; 2004;3:CD003794
41. Donohue JF, Kalberg C, Emmett A, Merchant K, Knobil K. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD. Treat Respir Med 2004;3:173-181
42. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81
43. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919
44. van Noord JA, Bantje TA, Eland ME, Korducki L, Cornelissen PJ. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax 2000;55:289-294
45. Casaburi R, Briggs DD Jr, Donohue JF, Serby CW, Menjoge SS, Witek TJ Jr. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. The US Tiotropium Study Group. Chest 2000;118:1294-1302
46. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224
47. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease: a three-center study. Am Rev Respir Dis 1989;139:1188-1191
48. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:778-784
49. Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1995;8:267-271
50. van Noord JA, Smeets JJ, Custers FL, Korducki L, Cornelissen PJ. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur Respir J 2002;19:639-644
51. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002;122:47-55
52. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399-404
53. McNicholas WT, Calverley PM, Lee A, Edwards JC. Long-acting inhaled anticholinergic therapy improves sleeping oxygen saturation in COPD. Eur Respir J 2004;23:825-831
54. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003;124:1743-1748
55. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840
56. Van Andel AE, Reisner C, Menjoge SS, Witek TJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest 1999;115:703-707
57. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002;121:1058-1069
58. Cazzola M, Di Lorenzo G, Di Perna F, Calderaro F, Testi R, Centanni S. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000;118:1576-1581
59. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001;119:1661-1670
60. Sturton G, Fitzgerald M. Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 2002;121(5 Suppl):192S-196S
61. Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet 2001;358:265-270
62. Bredenbröker D SJ, Leichtl S, Rathgeb F, Wurst W. Roflumilast, a new orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of chronic obstructive pulmonary disease [abstract]. Eur Respir J 2002;20(Suppl 38):374S
63. Agnew JE, Little F, Pavia D, Clarke SW. Mucus clearance from the airways in chronic bronchitis: smokers and ex-smokers. Bull Eur Physiopathol Respir 1982;18:473-484
64. Bennett WD, Chapman WF, Mascarella JM. The acute effect of ipratropium bromide bronchodilator therapy on cough clearance in COPD. Chest 1993;103:488-495
65. Bennett WD. Effect of beta-adrenergic agonists on mucociliary clearance. J Allergy Clin Immunol 2002;110(6 Suppl): S291-S297
66. Frohock JI, Wijkstrom-Frei C, Salathe M. Effects of albuterol enantiomers on ciliary beat frequency in ovine tracheal epithelial cells. J Appl Physiol 2002;92:2396-2402